Cognitive Neurology Unit Clinical Registry

Description

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

Conditions

Alzheimer Disease

Study Overview

Study Details

Study overview

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

Cognitive Neurology Unit's Anti-amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease Clinical Registry

Cognitive Neurology Unit Clinical Registry

Condition
Alzheimer Disease
Intervention / Treatment

-

Contacts and Locations

Boston

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease
  • * Patient has evidence of cognitive impairment on neuropsychological testing
  • * Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement
  • * Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease
  • * Amyloid PET imaging positive
  • * CSF p-Tau/Abeta42 ration \>0.023 and ABeta42 \< 1027\*\*
  • * 3T MRI in past 6 months
  • * Patient has a care partner
  • * Patient under the care of an appropriate BI-Lahey amyloid clinic
  • * Patient is on a stable medication regimen
  • * o Recent stroke or suspected TIA in the past year
  • * Pregnancy
  • * Active autoimmune or immunological disease
  • * Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives
  • * Bleeding disorder with Plts \< 50,000 or INR \> 1.5
  • * On warfarin, heparin, or DOAC
  • * On dual antiplatelet therapy
  • * Non Alzheimer disease cause of dementia/MCI
  • * ApoE e4 homozygote

Ages Eligible for Study

50 Years to 95 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Beth Israel Deaconess Medical Center,

Study Record Dates

2028-06